

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 July 2006 (06.07.2006)

PCT

(10) International Publication Number
WO 2006/071618 A1

(51) International Patent Classification:
A61K 38/13 (2006.01) A61P 1/16 (2006.01)

(21) International Application Number:
PCT/US2005/046058

(22) International Filing Date:
20 December 2005 (20.12.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/638,676 23 December 2004 (23.12.2004) US

(71) Applicant (for all designated States except US): NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant (for AT only): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventor; and

(75) Inventor/Applicant (for US only): WEIDMANN, Beat [US/US]; 47 Bacon Street, Winchester, Massachusetts 01890 (US).

(74) Agent: BAUTISTA, Regina, S.; NOVARTIS, CORPORATION INTELLECTUAL PROPERTY, One Health Plaza, Bldg. 104, East Hanover, New Jersey 07936-1080 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2006/071618 A1

(54) Title: COMPOUNDS FOR FLAVIVIRIDAE TREATMENT

(57) Abstract: Disclosed are non-immunosuppressive cyclophilin-binding cyclosporins, e.g. of formula (I), (Ia) or (II) as defined herein, having useful properties in the prevention or treatment of Flaviviridae infections and Flaviviridae induced disorders.

COMPOUNDS FOR FLAVIVIRIDAE TREATMENT

Field of the Invention

The present invention relates to a new use for non-immunosuppressive cyclosporins in the treatment of Flaviviridae viral infections and induced disorders.

Background of the invention

The cyclosporins comprise a class of structurally distinctive, cyclic, poly-N-methylated undecapeptides, commonly possessing pharmacological, in particular immunosuppressive, or anti-inflammatory activity. The first of the cyclosporins to be isolated was the naturally occurring fungal metabolite Cyclosporin or Cyclosporine, also known as cyclosporin A.

It is well established that cyclosporin A acts by interfering with the process of T cell activation by blocking transcription initiation of IL-2. Cyclosporin A has been shown to form a complex with a 17kD cytosolic protein named as cyclophilin, that occurs in many cell types and has been shown to be identical to peptidyl-prolyl cis-trans isomerase, an enzyme involved in protein folding.

However, it was found that binding to cyclophilin is a necessary but not a sufficient criterion for immunosuppressive activity. The cyclosporin A/cyclophilin complex can also associate with the cellular protein named calcineurin (CN) which belongs to the phosphatase superfamily. This binding abrogates its phosphatase activity, resulting in silencing of transcription factor NF-AT. The inhibition of the CN/NF-AT pathway is the essential mechanism for cyclosporin A mediated immunosuppression.

Cyclosporins which bind strongly to cyclophilin but are not immunosuppressive have been identified. A cyclosporin is considered to be non-immunosuppressive when it has an activity in the Mixed Lymphocyte Reaction (MLR) of no more than 5%, preferably no more than 2%, that of cyclosporin A. The Mixed Lymphocyte Reaction is described by T. Meo in "Immunological Methods", L. Lefkovits and B. Peris, Eds., Academic Press, N.Y. pp. 227 – 239 (1979). Spleen cells (0.5×10^6) from Balb/c mice (female, 8 – 10 weeks) are co-incubated for 5 days with 0.5×10^6 irradiated (2000 rads) or mitomycin C treated spleen cells from CBA mice (female, 8 – 10 weeks). The irradiated allogeneic cells induce a proliferative response in the Balb c spleen cells which can be measured by labeled precursors or incorporation into the DNA. Since the stimulator cells are irradiated (or mitomycin C treated) they do not respond to the Balb/c cells with proliferation but do retain their antigenicity. The IC_{50} found for the test compound in the MLR is compared with that found for cyclosporin A in

- 2 -

a parallel experiment. In addition, non-immunosuppressive cyclosporins lack the capacity of inhibiting CN and the downstream NF-AT pathway.

EP 0 484 281 A1 and U.S. Patent No. 5,767,069 disclose the use of non-immunosuppressive cyclosporins in the treatment of AIDS or AIDS-related disorders.

As disclosed in application EP 2004/009804, non-immunosuppressive cyclosporins which bind to cyclophilin have also been found to have an inhibitory effect on Hepatitis C virus (HCV).

Persistent infection by HCV, which has been identified as the major causative agent of non-A, non-B hepatitis has been considered closely related to liver diseases such as chronic hepatitis, liver cirrhosis or hepatocellular carcinoma. The development of these liver diseases is a major public health problem. Effective anti-HCV therapy is restricted to therapy with interferon or a combination of interferon and ribavirin. However, since the virus is not eliminated from about a half of the HCV patients treated with these known agents, there is still a strong need for alternative anti-HCV agents.

Hepatitis C infections or HCV induced disorders are e.g. chronic hepatitis, liver cirrhosis or liver cancer, e.g. hepatocellular carcinoma. The non-immunosuppressive cyclophilin-binding cyclosporins may also be used for example as a prophylactic treatment of neonates born to HCV infected mothers or of healthcare workers exposed to the virus, or of transplant recipients, e.g. organ or tissue transplant recipients, e.g. liver transplant, to eliminate possible recurrent HCV infection after transplantation.

HCV is the sole member of the genus *hepaciviruses*. *Hepaciviruses*, *flaviviruses* and *pestiviruses* are three distinct genera of the *Flaviviridae* family of viruses. The *flavivirus* genus includes more than 68 members separated into groups on the basis of serological relatedness (Calisher et al., *J. Gen. Virol.* 1993, 70:37-43). Clinical symptoms vary and include fever, encephalitis and hemorrhagic fever (*Fields Virology*, Eds: Fields, B.N., Knipe, D.M., and Howley, P.M., Lippincott Raven publishers, Philadelphia, PA, 1996, Chapter 31, 931-959). *Flaviviruses* of global concern that are associated with human disease include the dengue hemorrhagic fever viruses (DHF), yellow fever virus, shock syndrome and Japanese encephalitis virus (Halstead, S.B., *Rev. Infect. Dis.*, 1984, 6, 251-264; Halstead, S.B., *Science*, 239:476-481, 1988; Monath, T.P., *New Eng. J. Med.* 1988, 319, 641-643).

The *pestivirus* genus includes bovine viral diarrhea virus (BVDV), classical swine fever virus (CSFV, also called hog cholera virus) and border disease virus (BDV) of sheep

(Moennig, V. et al., *Adv. Vir. Res.* 1992, 41, 53-98). *Pestivirus* infections of domesticated livestock (cattle, pigs, and sheep) cause significant economic losses worldwide. BVD causes mucosal disease in cattle and is of significant economic importance to the livestock industry (Meyers, G. and Thiel, H.-J., *Advances in Virus Research*, 1996, 47, 53-118; Moening V., et al. *Adv. Vir. Res.* 1992, 41, 53-98). Human *pestiviruses* have not been as extensively characterized as the animal *pestiviruses*. However, serological surveys indicate considerable *pestivirus* exposure in humans.

Pestiviruses and *hepaciviruses* are closely related virus groups within the *Flaviviridae* family. Other closely related viruses in this family include the GB virus A, GB virus A-like agents, GB virus-B and GB virus-C (also called hepatitis G virus, HGV). The *hepacivirus* group (hepatitis C virus; HCV) consists of a number of closely related but genotypically distinguishable viruses that infect humans. There are approximately 6 HCV genotypes and more than 50 subtypes. Due to the similarities between *pestiviruses* and *hepaciviruses*, combined with the poor ability of *hepaciviruses* to grow efficiently in cell culture, bovine viral diarrhea virus (BVD) is often used as a surrogate to study the HCV virus.

The genetic organization of *pestiviruses* and *hepaciviruses* is very similar. These positive stranded RNA viruses possess a single large open reading frame (ORF) encoding all the viral proteins necessary for virus replication. These proteins are expressed as a polyprotein that is co- and post-translationally processed by both cellular and virus-encoded proteinases to yield the mature viral proteins. The viral proteins responsible for the replication of the viral genome RNA are located within approximately the carboxy-terminal. Two-thirds of the ORF are termed nonstructural (NS) proteins. The genetic organization and polyprotein processing of the nonstructural protein portion of the ORF for *pestiviruses* and *hepaciviruses* is very similar. For both the *pestiviruses* and *hepaciviruses*, the mature nonstructural (NS) proteins, in sequential order from the amino-terminus of the nonstructural protein coding region to the carboxy-terminus of the ORF, consist of p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B. The genetic organization of HCV is depicted in Figure 1.

The NS proteins of *pestiviruses* and *hepaciviruses* share sequence domains that are characteristic of specific protein functions. For example, the NS3 proteins of viruses in both groups possess amino acid sequence motifs characteristic of serine proteinases and of helicases (Gorbalenya et al. (1988) *Nature* 333:22; Bazan and Fletterick (1989) *Virology* 171:637-639; Gorbalenya et al. (1989) *Nucleic Acid Res.* 17:3889-3897). Similarly, the NS5B proteins of *pestiviruses* and *hepaciviruses* have the motifs characteristic of RNA-

directed RNA polymerases (Koonin, E.V. and Dolja, V.V. (1993) *Crit. Rev. Biochem. Molec. Biol.* 28:375-430).

The actual roles and functions of the NS proteins of *pestiviruses* and *hepaciviruses* in the lifecycle of the viruses are directly analogous. In both cases, the NS3 serine proteinase is responsible for all proteolytic processing of polyprotein precursors downstream of its position in the ORF (Wiskerchen and Collett (1991) *Virology* 184:341-350; Bartenschlager et al. (1993) *J. Virol.* 67:3835-3844; Eckart et al. (1993) *Biochem. Biophys. Res. Comm.* 192:399-4067; Grakoui et al. (1993) *J. Virol.* 67:2832-2843; Grakoui et al. (1993) *Proc. Natl. Acad. Sci. USA* 90:10583-10587; Hijikata et al. (1993) *J. Virol.* 67:4665-4675; Tome et al. (1993) *J. Virol.* 71:5312-5322). The NS3 proteins of both viruses also function as a helicase (Kim et al. (1995) *Biochem. Biophys. Res. Comm.* 215:160-166; Jin and Peterson (1995) *Arch. Biochem. Biophys.*, 323:47-53; Warrenner and Collett (1995) *J. Virol.* 69:1720-1726). Finally, the NS5B proteins of *pestiviruses* and *hepaciviruses* have the predicted RNA-directed RNA polymerase activity (Behrens et al. (1996) *EMBO J.* 15:12-22; Lechmann et al. (1977) *J. Virol.* 71:8416-8428; Yuan et al. (1997) *Biochem. Biophys. Res. Comm.* 232:231-235; Hagedorn, PCT WO 97/12033; Zhong et al. (1998) *J. Virol.* 72:9365-9369).

The present invention provides the use of non-immunosuppressive cyclophilin-binding cyclosporins in the prevention or treatment of Flaviviridae virus infections and induced disorders.

Detailed Description of the Invention

In accordance with the present invention, there are provided pharmaceutical compositions and combinations comprising a non-immunosuppressive cyclosporin and methods of treating Flaviviridae viral infections and induced disorders using the same.

Flaviviruses included within the scope of this invention are discussed generally in *Fields Virology*, Editors: Fields, N., Knipe, D.M. and Howley, P.M.; Lippincott-Raven Publishers, Philadelphia, PA; Chapter 31 (1996). Specific flaviviruses include, without limitation: Absettarov; Alfuy; Apoi; Aroa; Bagaza; Banzi; Bououi; Bussuquara; Cacipacore; Carey Island; Dakar bat; Dengue viruses 1, 2, 3 and 4; Edge Hill; Entebbe bat; Gadgets Gully; Hanzalova; Hypr; Ilheus; Israel turkey meningoencephalitis; Japanese encephalitis; Jugra; Jutiapa; Kadam; Karshi; Kedougou; Kokoera; Koutango; Kumlinge; Kunjin; Kyasanur Forest disease; Langat; Louping ill; Meaban; Modoc; Montano myotis leukoencephalitis; Murray valley encephalitis; Naranjal; Negishi; Ntaya; Omsk Hemorrhagic fever; Phnom-penh bat; Powassan; Rio Bravo; Rocio; Royal Farm; Russian spring-summer encephalitis;

- 5 -


Saboya; St. Louis encephalitis; Sal Vieja; San Perlita; Saumarex Reef; Sepik; Sokuluk; Spondweni; Stratford; Temusu; Tyuleny; Uganda S, Usutu, Wesselsbron; West Nile; Yaounde; Yellow fever; and Zika.

Pestiviruses included within the scope of this invention are also discussed generally in *Fields Virology* (Id.). Specific pestiviruses include, without limitation: bovine viral diarrhea virus ("BVDV"); classical swine fever virus ("CSFV") also known as hog cholera virus; and border disease virus ("BDV").

Other members of the Flaviviridae family within the scope of the present invention include but are not limited to GB virus A, GB virus A-like agents, GB virus-B and GB virus-C (also called hepatitis G virus, HGV). In addition, the *hepacivirus* group (hepatitis C virus; HCV), including the approximately 6 HCV genotypes and more than 50 subtypes are also within the scope of the present invention.

A cyclosporin is considered as binding to cyclophilin if it binds to human recombinant cyclophilin at least one fifth as well as does cyclosporin A in the competitive ELISA test described by Quesniaux in Eur. J. Immunol. 1987 17 1359 – 1365. In this test, the cyclosporin to be tested is added during the incubation of cyclophilin with coated BSA-cyclosporin A and the concentration required to give a 50% inhibition of the control reaction without competitor is calculated (IC_{50}). The results are expressed as the Binding Ratio (BR), which is the log to the base 10 of the ratio of the IC_{50} of the test compound and the IC_{50} in a simultaneous test of cyclosporin A itself. Thus a BR of 1.0 indicates that the test compound binds human cyclophilin one factor of ten less well than does cyclosporin A, and a negative value indicates binding stronger than that of cyclosporin A. The cyclosporins active against HCV have a BR lower than 0.7, preferably equal to or lower than zero.

Examples of non immunosuppressive cyclophilin-binding cyclosporins include e.g. compounds of Formula I



wherein

W is MeBmt, dihydro-MeBmt, 8'-hydroxy-MeBmt or O-acetyl-MeBmt¹;

X is α Abu, Val, Thr, Nva or O-methyl threonine (MeOThr);

R is Pro, Sar, (D)-MeSer, (D)-MeAla, or (D)-MeSer(Oacetyl);

- 6 -

Y is MeLeu, thioMeLeu, γ -hydroxy-MeLeu, Melle, MeVal, MeThr, MeAla, Mealle or MeaThr; N-ethylVal, N-ethylIle, N-ethylThr, N-ethylPhe, N-ethylTyr or N-ethylThr(Oacetyl)

Z is Val, Leu, MeVal or MeLeu,


Q is MeLeu, γ -hydroxy-MeLeu, MeAla or Pro,

T₁ is (D)Ala or Lys,

T₂ is MeLeu or γ -hydroxy-MeLeu, and

T₃ is MeLeu or MeAla.

Preferred compounds of formula I are e.g. compounds of formula Ia



in which W' is MeBmt, dihydro-MeBmt or 8'-hydroxy-MeBmt;

X is α Abu, Val, Thr, Nva or O-methyl threonine (MeOThr);

R' is Sar, (D)-MeSer, (D)-MeAla, or (D)-MeSer(Oacetyl);

Y' is MeLeu, γ -hydroxy-MeLeu, Melle, MeVal, MeThr, MeAla,

Mealle or MeaThr; N-ethylVal, N-ethylIle, N-ethylThr, N-ethylPhe, N-ethylTyr or N-ethylThr(Oacetyl)

Z is Val, Leu, MeVal or MeLeu; and

Q' is MeLeu, γ -hydroxy-MeLeu or MeAla.

The groups W', X, Y', Z, Q' and R' have, independently, the following preferred significances:

W' is preferably W'' where W'' is MeBmt or dihydro-MeBmt;

X is preferably X' where X' is α Abu or Nva, more preferably X'' where X'' is α Abu;

R' is preferably R'' where R'' is Sar;

Y' is preferably Y'' where Y'' is γ -hydroxy-MeLeu, MeVal, MeThr, Melle, N-ethylIle or N-ethylVal;

Z is preferably Z' where Z' is Val or MeVal; and

Q' is preferably Q'' where Q'' is MeLeu;


A preferred group of Compounds of formula Ia are those in which W' is W'', X is X', Y' is Y'', Z is Z', Q' is Q'' and R' is R''.

Examples of preferred compounds of Formula Ia are e.g.:

- a) [dihydro-MeBmt]¹-[γ-hydroxy-MeLeu]⁴-Ciclosporin; BR* = 0.1; IR<1%
- b) [MeVal]⁴-Ciclosporin; BR = 0.1; IR<1%
- c) [Melle]⁴-Ciclosporin; BR = -0.2; IR <1%
- d) [MeThr]⁴-Ciclosporin;
- e) [γ-hydroxy-MeLeu]⁴-Ciclosporin; BR = 0.4; IR<1%
- f) [Ethyl-Ile]⁴-Ciclosporin; BR = 0.1; IR <2%
- g) [Ethyl-Val]⁴-Ciclosporin; BR = 0; IR <2%
- h) [Nva]²-[γ-hydroxy-MeLeu]⁴-Ciclosporin;
- i) [γ-hydroxy-MeLeu]⁴-[γ-hydroxy-MeLeu]⁶-Ciclosporin;
- j) [MeVal]⁵-Ciclosporin; BR = 0.4; IR = 5.3%
- k) [MeOThr]²-[(D)MeAla]³-[MeVal]⁵-Ciclosporin;
- j) [8'-hydroxy-MeBmt]¹-Ciclosporin; BR = 0.35; IR= 1.8%
- k) [MeAla]⁶-Ciclosporin; BR = -0.4; IR = 3.2
- l) [γ-hydroxy-MeLeu]⁹-Ciclosporin; BR = 0.15; IR = 2.9


IR = Immunosuppressive Ratio, expressed as a percentage of the activity relative to Cyclosporin A.

Further examples of non-immunosuppressive cyclosporins are the compounds disclosed in WO 98/28330, WO 98/28329 and WO 98/28328, the contents thereof being incorporated herein by reference, e.g. compounds of formula II .



wherein

W_a is



- 8 -


wherein R_a is a residue of formula Ic or Id



in which R_4 is C_{1-4} alkylthio, amino C_{1-4} alkylthio, C_{1-4} alkylamino C_{1-4} alkylthio, di C_{1-4} alkylamino- C_{1-4} alkylthio, pyrimidinylthio, thiazolylthio, N- C_{1-4} alkylimidazolylthio, hydroxy C_{1-4} alkylphenylthio, hydroxy C_{1-4} alkylphenoxy, nitrophenylamino or 2-oxopyrimidin-1-yl, and R'_4 is C_{1-4} alkyl,

X_a is Abu;

R_a is $\text{---NMe---CH(R}_b\text{)---CO---}$ wherein R_b is H or ---S---Alk---R_0 in which Alk- R_0 is methyl; or Alk is straight or branched C_{2-6} alkylene or C_{3-6} cycloalkylene and R_0 is H; OH; COOH; C_{2-5} alkoxy-carbonyl; NR_1R_2 in which each of R_1 and R_2 , independently, is selected from H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{3-6} cycloalkyl and phenyl each optionally substituted by halogen, C_{1-4} alkoxy, C_{2-5} alkoxycarbonyl, amino, C_{1-4} alkylamino and/or di C_{1-4} alkyl-amino, and benzyl and a heterocyclic radical, said benzyl and heterocyclic radicals being saturated or unsaturated and containing 5 or 6 ring members and 1 to 3 heteroatoms, or R_1 and R_2 form, together with the nitrogen atom to which they are attached, a 4- to 6 membered heterocycle which may contain another heteroatom chosen from nitrogen, oxygen and sulphur, and which is optionally substituted by C_{1-4} alkyl, phenyl or benzyl; or each of R_1 and R_2 , independently, is a radical of formula Ib



in which R_1 and R_2 are as defined above, R_3 is H or C_{1-4} alkyl and n is an integer ranging from 2 to 4;

Y_a is MeLeu or γ -hydroxy-MeLeu;

Z_a is Val; and

Q_a is MeLeu,

with the proviso that R_b is not H when Y_a is MeLeu,
or a pharmaceutically acceptable salt thereof.

In the formula II, when R_1 and/or R_2 is a heterocyclic residue, it may be pyridyl, tetrahydropyridyl, piperidyl, imidazolyl, oxazolyl or thiazolyl. When R_1 and R_2 form a heterocyclic

- 9 -

residue with the nitrogen atom to which they are attached, by way of example, the heterocyclic residue may be chosen from azetidiny, piperidyl, piperaziny, N-methyl-piperaziny, N-phenylpiperaziny, N-benzylpiperaziny, pyridyl, imidazolyl, morpholino, thiomorpholino, tetrahydropyridyl, methyltetrahydropyridyl (for example 4-methyl-tetrahydropyridyl) or phenyltetrahydropyridyl (for example 4-phenyltetrahydropyridyl).

The Compounds of formula I, Ia or II may be obtained in a variety of ways, which may be classified as:

- 1) Fermentation
- 2) Biotransformation
- 3) Derivatisation
- 4) Partial Synthesis
- 5) Total Synthesis

as disclosed e.g. in EP 0 484 281 A1, WO 00/01715, WO 98/28330, WO 98/28329 or WO 98/28328 the contents thereof being incorporated herein by reference.

In a series of further specific or alternative embodiments, the present invention also provides:

- 1.1 A method for preventing or treating Flaviviridae infections or Flaviviridae induced disorders in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a non-immunosuppressive cyclophilin-binding cyclosporin, e.g. a compound of formula I, Ia or II.
According to the invention, the non-immunosuppressive cyclophilin-binding cyclosporine may be administered in an amount effective to alleviate or eliminate one or more of the signs or symptoms of Flaviviridae infection or induced disorder, for example, effective to lower the Flaviviridae virus measured in a serum sample of a subject.
- 1.2 A method for inhibiting Flaviviridae replication in a medium, comprising applying to this medium an effective amount of a non-immunosuppressive cyclophilin-binding cyclosporin, e.g. a compound of formula I, Ia or II.
- 1.3 A method for inhibiting Flaviviridae replication in a subject in need thereof, comprising administering to this subject a therapeutically effective amount of a non-immunosuppressive cyclophilin-binding cyclosporin, e.g. a compound of formula I, Ia or II.
- 1.4 A method for preventing the recurrence of HCV infection in a transplant recipient in need thereof, comprising administering to said recipient a therapeutically effective

amount of a non-immunosuppressive cyclophilin-binding cyclosporin, e.g. a compound of formula I, Ia or II.

2. Use of a non-immunosuppressive cyclophilin-binding cyclosporin, e.g. a compound of formula I, Ia or II, in the preparation of a pharmaceutical composition for use in any method as defined above.
3. A pharmaceutical composition for use in any method as defined above, comprising a non-immunosuppressive cyclophilin-binding cyclosporin, e.g. a compound of formula I, Ia or II, together with one or more pharmaceutically acceptable diluents or carriers therefor.

Utility of the non-immunosuppressive cyclophilin-binding cyclosporins (hereinafter "cyclosporins of the invention" or "subject non-immunosuppressive cyclosporin") in treating diseases and conditions as hereinabove specified may be demonstrated in standard animal or clinical tests, e.g. in accordance with the methods described hereinafter.

A. In vitro

Cell culture: Huh-7 and MH-14 cells, HCV replicon cells, are cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS). PH5CH8 cells are cultured in a 1:1 mixture of DMEM and F12 medium supplemented with 100 ng/ml of epidermal growth factor, 10 μ /ml of insulin, 0.36 μ g/ml of hydrocortisone, 5 μ g/ml of transferrin, 5 μ g/ml of linoleic acid, 20 ng/ml of selenium, 4 μ g/ml of glucagon, 10 ng/ml of prolactin, 10 μ g/ml of gentamicin, 200 μ g/ml of kanamycin, and 2 % FBS.

Immunoblot analysis: Immunoblot analysis is performed as described by K. Watashi et al., Virology 2001, 286, 391 – 402. The primary antibodies used in this experiment are anti-NS5A, anti-NS5B, and anti- β -actin (Sigma) antibodies.

Indirect immunofluorescence analysis: Indirect immunofluorescence analysis is performed as described by K. Watashi, supra. The primary antibodies used in this experiment are anti-NS5A and anti-PDI (StressGen) antibodies.

Reverse transcription (RT)-polymerase chain reaction (PCR) analysis

Total RNA of cultured cells is isolated with Sepasol-RNA I Super (nacalai tesque) as recommended by the manufacturer. RT-PCR analysis is performed using a one step RNA PCR kit (Takara) according to the manufacturer's directions. The primers used for detection of mRNAs for 2', 5'-oligoadenylate synthetase and double strand RNA-dependent protein kinase are 5'-CCGTGAAGTTTGAGGTCCAG-3', 5'-GACTAATTCCAAGACCGTCCG-3' and

5'-TGGCCGCTAAACTTGCATATC-3', 5'-GCGAGTGTGCTGGTCACTAAAG-3', respectively.

Northern blot analysis: Northern blot analysis is performed as described by H. Kishine et al., Biochem. Biophys. Res. Commun., 2002, 47, 119 – 125. The probe complementary to the NS5B sequence used in this experiment is described by H. Kishine, supra.

Real time RT-PCR analysis: The 5'-UTR of HCV genome RNA is quantified using the ABI PRISM 7700 sequence detector (Applied Biosystems) as described by T. Takeuchi et al., Gastroenterology, 1999, 116, 636 – 642. The forward and reverse primers used in this experiment are 5'-CGGGAGAGCCATAGTGG-3' and 5'-AGTACCACAAGGCCTTTCG-3', respectively. The fluorogenic probe is 5'-CTGCGGAACCGGTGAGTACAC-3'. As an internal control, ribosomal RNA is also quantified using TaqMan Ribosomal RNA Control Reagents (Applied Biosystems).

In vitro HCV infection experiment: The in vitro HCV infection experiment is performed essentially as described by N. Kato et al., Jpn. J. Cancer Res. 1996, 87, 787 – 792 and M. Ikada et al., Virus Res., 1998, 56, 157 – 167. PH5CH8 cells (1×10^5) are infected with the plasma 1B-2 (equivalent to 10^4 to 10^5 HCV RNA copies), which is prepared from an HCV-positive blood donor. At 24 h post-inoculation, the cells are washed three times with phosphate-buffered saline (PBS) and maintained with fresh medium.

Transfection and reporter assay: Transfection into MH-14 and H9 cells is performed using FuGENE 6 (Roche) and Lipofectamine 2000 transfection reagent (Invitrogen), respectively, according to the manufacturer's protocol. The reporter assay is performed as described by K. Watashi, supra. The reporter plasmids used in this study are pNFAT-Luc, pAP1-Luc, pNFkB-Luc (PathDetect Reporter System; Stratagene), and pRL-TK (Dual-luciferase reporter assay system; Promega).

The effect of various cyclosporins of the invention on the replication of the HCV genome using MH-14 cells, in which the HCV subgenomic replicon as shown in Fig. 1A is autonomously replicated. Treatment with a cyclosporin of the invention, e.g. [Melle]⁴-cyclosporin, e.g. at 1 µg/ml, as well as 100 U/ml IFN α which is used as a positive control for 7 days decreases the amount of HCV NS5A and NS5B proteins to levels undetectable by immunoblot analysis. Indirect immunofluorescence analysis showed that NS5A protein production is reduced in all the cells treated with 1 µg/ml cyclosporin of the invention, while the level of protein disulfide isomerase (PDI), which is an endoplasmic reticulum marker, as

- 12 -

an internal control is not altered under this condition. The cyclosporins of the invention decrease in this assay HCV protein expression in HCV replicon cells.

Replicon RNA is analyzed in MH-14 cells treated with or without a cyclosporin of the invention or IFN α for 7 days by northern blot analysis. Treatment with e.g. 1 μ g/ml cyclosporin of the invention, e.g. [Melle]⁴-cyclosporin, decreases the amount of replicon RNA to an undetectable level. Treatment with 100U/ml IFN α produces a similar effect. In addition the titer is gradually decreased and the level of HCV RNA is reduced to about 1/400 of the original on the 7th day. In the case of a co-treatment with IFN α , a further reduction at any time point examined (3th, 5th and 7th day) compared with the single treatment with either the cyclosporin or IFN α : the replicon RNA level in MH-14 cells treated with both the cyclosporin and IFN α for 7 days is significantly decreased over that in the cells treated with IFN α alone.

Furthermore, PH5CH8 cells (non-neoplastic hepatocyte cell line) are treated with HCV-positive plasma and subsequently the HCV RNA genome titer at various time-points post-inoculation is quantified by real time RT-PCR analysis. While the HCV RNA genome titer on the 5th day post-inoculation in the cells is increased about 10-fold compared with that on the 1st day, a significant increase of the HCV RNA genome titer at these time points was not observed in the cells treated continuously with a cyclosporin of the invention, e.g. [Melle]⁴-cyclosporin, or IFN α . The cyclosporins of the invention inhibit the replication of HCV infected cultured hepatocytes.

Results are shown in Fig. 2E, 2F and 2G: immunoblot analysis (2E), indirect immunofluorescence analysis (2F) and real time RT-PCR analysis (2G) is performed using MH-14 cells treated with [Melle]⁴-Cyclosporin (■) or a non cyclophilin binding cyclosporin (●), e.g. 6-[[R-(E)]-6,7-Didehydro-N,4-dimethyl-3-oxo-L-2-aminooctanoic acid]-7-L-valine-cyclosporin A. Control in 2E and 2F (1st row), no treatment; CysA in 2E, 1 μ g/ml ; [Melle]⁴-Cyclosporin in 2E (■) and 2F (■), 1 μ g/ml; the non cyclophilin binding cyclosporin in 2E (●) and 2F (●), 1 μ g/ml.

Further cell culture systems for determining antiviral activities

The methods described above and some of the methods described below utilize HCV. The described methods however, may be adapted to other members of the Flaviviridae family simply by changing the cell system and viral pathogen.

A useful cell-based assay to detect HCV and its inhibition assesses the levels of replicon RNA from Huh7 cells harbouring the HCV replicon. These cells can be cultivated in standard media, for example DMEM medium (high glucose, no pyruvate), supplemented with 10% fetal bovin serum, 1x non-essential amino acids, Pen-Strep-Glu (100 units/liter, 100 microgram/liter, and 2.92 mg/liter, respectively), and G418 (500 to 1000 microgram/millilitre). Antiviral screening assays can be done in the same medium without G418. To keep the cells in the logarithmic growth phase, cells are seeded in 96-well plates at low density, as for example, 1000 cells per well. The test compound i.e., a subject non-immunosuppressive cyclosporin, is then added immediately after seeding the cells and they are incubated for 3 to 7 days at 37°C in an incubator. The medium is then removed, and the cells prepared for total RNA extraction (replicon RNA + host RNA). Replicon RNA can then be amplified in a real-time RT-PCR (Q-RT-PCR) protocol, and quantified.

The observed differences in quantification of replicon RNA are one way to express the antiviral potency of the test compound, i.e., a subject non-immunosuppressive cyclosporin. In a typical experiment, a comparable amount of replicon is produced in the negative control and with non-active compounds. This can be concluded if the measured threshold-cycle for the flavivirus or pestivirus RT-PCR in both settings is approximately the same. In such experiments, a way to express the antiviral effectiveness of a compound is to subtract the average threshold RT-PCR cycle of the negative control ($C_{t_{negative}}$) from the threshold RT-PCR cycle of the test compound ($C_{t_{testcompound}}$). This value is called ΔCt ($\Delta Ct = C_{t_{testcompound}} - C_{t_{negative}}$). A ΔCt value of 3.3 represents a 1-log reduction in replicon production. As a positive control, recombinant interferon alpha-2a (for example, Roferon-A, Hoffmann-Roche, NJ, USA) can be used alongside the test compound, i.e., a subject non-immunosuppressive cyclosporin. Furthermore, the compounds can be tested in dilution series (typically at 100, 33, 10³ and 1:M). The ΔCt values for each concentration allow the calculation of the 50% effective concentration (EC_{50}).

As discussed earlier, the assays described above can be adapted to the other members of the *Flaviviridae* by changing the cell system and the viral pathogen. Methodologies to determine the efficacy of a subject non-immunosuppressive cyclosporin include modifications of the standard techniques as described by Holbrook MR et al. *Virus Res.* 2000, 69, 31; Markland W. et al. *Antimicrob. Agents. Chemother.* 2000, 44, 859; Diamond MS et al., *J. Virol.* 2000, 74, 7814; Jordan I et al. *J. Infect Dis.* 2000, 182, 1214; Sreenivasan V et al. *J. Virol. Methods* 1993, 45 (1), 1; or Baginski SG et al. *Proc. Natl. Acad.*

Sci USA 2000, 97 (14) 7981 or the real-time RT-PCR technology. As an example, an HCV replicon system in HuH7 cells (Lohmann V et al. *Science*, 1999, 285 (5424, 110) or modifications thereof (Blight et al. 2000) can be used.

Cell Protection Assay

An assay may be performed essentially as described by Baginski, S.G., et al. "Mechanism of action of a pestivirus compound" *PNAS USA* 2000, 97(14), 7981-7986. MDBK cells (ATCC) are seeded onto 96-well culture plates (4,000 cells per well) 24 hours before use. After infection with BVDV (strain NADL, ATCC) at a multiplicity of infection (MOI) of 0.02 plaque forming units (PFU) per cell, serial dilutions of a subject non-immunosuppressive cyclosporin may be added to both infected and uninfected cells in a final concentration of 0.5% DMSO in growth medium. Each dilution may be tested in duplicate, triplicate or quadruplicate. Cell densities and virus inocula can be adjusted to ensure continuous cell growth throughout the experiment and to achieve more than 90% virus-induced cell destruction in the untreated controls after four days post-infection. After four days, plates are fixed with 50% TCA and stained with sulforhodamine B. The optical density of the wells may be read in a microplate reader at 550 nm. The 50% effective concentration (EC_{50}) values are defined as the concentration of a subject non-immunosuppressive cyclosporin that achieved 50% reduction of cytopathic effect of the virus.

Plaque Reduction Assay

Effective concentrations for a subject non-immunosuppressive cyclosporin may be determined in duplicate 24-well plates by plaque reduction assays. Cell monolayers are infected with 100 PFU/well of virus. Then, serial dilutions of a subject non-immunosuppressive cyclosporin in MEM supplemented with 2% inactivated serum and 0.75% of methyl cellulose are added to the monolayers. Cultures are further incubated at 37C for 3 days, then fixed with 50% ethanol and 0.8% Crystal Violet, washed and air-dried. Plaques are counted to determine the concentration to obtain 90% virus suppression.

Yield Reduction Assay

For each subject non-immunosuppressive cyclosporin, the concentration to obtain a 6-log reduction in viral load may be determined in duplicate 24-well plates by yield reduction assays. The assay may be performed as described in Baginski, S.G., et al. "Mechanism of action of a pestivirus compound" *PNAS USA* 2000, 97(14), 7981-7986, with minor modifications. MDBK cells are seeded onto 24-well plates (2×10^5 cells per well) 24 hours

- 15 -

before infection with BVDV (NADL strain) at a multiplicity of infection (MOI) of 0.1 PFU per cell. Serial dilutions of non-immunosuppressive cyclosporins are added to cells in a final concentration of 0.5% DMSO in growth medium. Each dilution may be tested in duplicate, triplicate, or quadruplicate. After three days, cell cultures (cell monolayers and supernatants) are lysed by multiple freeze-thaw cycles, and virus yield quantified by plaque assay. Briefly, MDBK cells are seeded onto 6-well plates (5x10⁵ cells per well) 24 hours prior to use. Cells are inoculated with 0.2 mL of test lysates for 1 hour, washed and overlaid with 0.5% agarose in growth medium. After 3 days, cell monolayers are fixed with 3.5% formaldehyde and stained with 1% crystal violet (w/v in 50% ethanol) to visualize plaques. The plaques are then counted to determine the concentration to obtain a 6-log reduction in viral load.

Non-cell based assays adapted for detecting Flaviviridae viruses

Nucleic acid amplification technology is now the method of choice for identification of a large and still growing number of microorganisms such as *Mycobacterium tuberculosis*, human immunodeficiency virus (HIV), and hepatitis C virus (HCV) in biological samples. Nucleic acid amplification techniques include the polymerase chain reaction (PCR), ligase chain reaction (LCR), nucleic acid sequence-based amplification (NASBA), strand-displacement amplification (SDA), and transcription-mediated amplification (TMA). The nucleotide sequence for at least a portion of a Flaviviridae virus genome is required for nucleic acid amplification techniques. Such sequences are readily available in the published literature and genetic databases.

Amplified-Product Detection Schemes

Amplified-product detection schemes are of two basic types: heterogeneous and homogeneous. Heterogeneous detection is characterized by a distinct step, such as washing, designed to remove unhybridized probes from hybridised probes, whereas in homogeneous detection there is no physical separation step to remove free probe from bound probe. Multiple heterogeneous and homogeneous detection methods exist.

Heterogeneous Detection

Southern blotting, for example, is a heterogeneous detection technique. In Southern blotting, electrophoresis is used to separate amplification products by size and charge. The size-fractionated products are transferred to a membrane or filter by diffusion, vacuuming, or electroblotting. Labelled detection probes are then hybridised to the membrane-bound

targets in solution, the filters are washed to remove any unhybridized probe, and the hybridised probe on the membrane is detected by any of a variety of methods.

Other types of heterogeneous detection are based on specific capture of the amplification products by means of enzyme-linked immunosorbent assays (ELISAs). One method used with PCR involves labelling one primer with a hapten or a ligand, such as biotin, and, after amplification, capturing it with an antibody- or streptavidin-coated microplate. The other primer is labelled with a reporter such as fluorescein, and detection is achieved by adding an ant fluorescein antibody, horseradish peroxidase (HRP) conjugate. This type of method is not as specific as using detection probes that hybridise to defined amplification products of interest.

Homogeneous Detection

Because hybridised and nonhybridized detection probes are not physically separated in homogeneous detection systems, these methods require fewer steps than heterogeneous methods and thus are less prone to contamination. Among the commercially available kits that use homogeneous detection of fluorescent and chemiluminescent labels are the TaqMan system (Applied Biosystems; Foster City, CA), BDPProbeTecET system (Becton Dickinson; Franklin Lakes, NJ), QPCR System 5000 (Perkin-Elmer Corp.; Norwalk, CT) and Hybridization Protection Assay (Gen Probe Inc.; San Diego).

The TaqMan system detects amplicon in real time. The detection probe, which hybridizes to a region inside the amplicon, contains a donor fluorophore such as fluorescein at its 5' end and a quencher moiety, for example, rhodamine, at its 3' end. When both quencher and fluorophore are on the same oligonucleotide, donor fluorescence is inhibited. During amplification the probe is bound to the target. Taq polymerase displaced and cleaves the detection probe as it synthesizes the replacement strand. Cleavage of the detection probe results in separation of the fluorophore from the quencher, leading to an increase in the donor fluorescence signal. During each cycle of amplification the process is repeated. The amount of fluorescent signal increases as the amount of amplicon increases.

Molecular beacons use quenchers and fluorophores also. Beacons are probes that are complementary to the target amplicon, but contain short stretches (approximately 5 nucleotides) of complementary oligonucleotides at each end. The 5' and 3' ends of the beacons are labelled with a fluorophore and a quencher, respectively. A hairpin structure is formed when the beacon is not hybridised to a target, bringing into contact the fluorophore and the quencher and resulting in fluorescent quenching. The loop region contains the

- 17 -

region complementary to the amplicon. Upon hybridization to a target, the hairpin structure opens and the quencher and fluorophore separate, allowing development of a fluorescent signal. A fluorometer measures the signal in real time.

The BDProbeTecET system uses a real-time detection method that combines aspects of TaqMan and molecular beacons. The probe has a hairpin loop structure and contains fluorescein and rhodamine labels. In this system, however, the region complementary to the target molecule is not within the loop but rather in the region 3' to the rhodamine label. Instead of containing the sequence complementary to the target, the single-stranded loop contains a restriction site for the restriction enzyme BsoBI. The single-stranded sequence is not a substrate for the enzyme. The fluorescein and rhodamine labels are near each other before amplification, which quenches the fluorescein fluorescence. Strand-displacement amplification converts the probe into a double-stranded molecule. The BsoBI restriction enzyme can then cleave the molecule, resulting in separation of the labels and an increase in the fluorescent signal.

The QPCR System 5000 employs electrochemiluminescence with ruthenium labels. A biotinylated primer is used. After amplification, the biotin products are captured on streptavidin-coated paramagnetic beads. The beads are transferred into an electrochemical flow cell by aspiration and magnetically held to the surface of the electrode. Upon electrical stimulation, the ruthenium-labeled probe emits light.

Detection-probe design is critical in all methodologies that use probes to detect amplification products. Good detection probes hybridise only to specified amplification product and do not hybridise to non-specific products. Other key issues in optimising detection methodologies involve the labelling of probes and the maximization of sample throughput.

Labelling Methods and Reporter Molecules

Detection probes can be labeled several different ways. Enzymatic incorporation of ^{32}P or ^{35}S into the probes is the most common method for isotopical labeling. Following hybridisation and washing, the signal is detected on autoradiographic film.

To perform nonradioactive detection, probes can be enzymatically labelled with a variety of molecules. Biotin can be incorporated enzymatically and then detected with streptavidin-conjugated alkaline phosphatase, using AP substrates like 5-bromo-4-chloro-3-indolyl phosphate (BCIP) and nitroblue tetrazolium (NBT). Chemiluminescent substrates

- 18 -

such as Lumi-Phos 530 or Lumi-Phos Plus (Lumigen, Southfield, MI) can also be used with AP. In addition, digoxigenin-11-dUTP can be incorporated enzymatically into DNA or RNA, and antidigoxigenin AP conjugates can be used with colorimetric or chemiluminescent detection.

There are numerous other types of reporter molecules, including chemiluminescent moieties such as acridinium esters. Many fluorescent moieties are available as well. Electrochemiluminescent compounds such as tris (2,2'-bipyridine) ruthenium (II) can be used also. Further discussions of these and similar techniques can be found in: Schiff ER, de Medina M, Kahn RS. *Semin Liver Dis.* 1999; 19 (Suppl 1:3-15).

Any of these heterogeneous or homogeneous assays may be utilized to assess the effectiveness of the cyclosporins of the invention against a virus of the Flaviviridae family.

B. Clinical Trial

A total of 15 patients with chronic Hepatitis C infection or other Flaviviridae virus infection, are enrolled in a study of 2 weeks. Each patient receives a cyclosporine of the invention, e.g. [Melle]⁴-ciclosporin, at a dose of 7 to 15 mg/kg p.o. The serum levels of Hepatitis C antigens (or other Flaviviridae virus antigens) are determined at day 0 and day 14 in each patient.

A person suffering from hepatitis C infection may exhibit one or more of the following signs or symptoms: (a) elevated ALT, (b) positive test for anti-HCV antibodies, (c) presence of HCV as demonstrated by a positive test for HCV-RNA, (d) clinical stigmata of chronic liver disease, (e) hepatocellular damage. Such criteria may not only be used to diagnose Hepatitis C, but can be used to evaluate a patient's response to drug treatment.

Elevated serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are known to occur in uncontrolled Hepatitis C, and a complete response to treatment is generally defined as the normalization of these serum enzymes, particularly ALT (Davis et al., 1989, New Eng. J. Med. 321:1501-1506). ALT is an enzyme released when liver cells are destroyed and is symptomatic of HCV infection.

In order to follow the course of HCV replication or other Flaviviridae virus replication in subjects in response to drug treatment, the virus RNA may be measured in serum samples by, for example, a nested polymerase chain reaction assay that uses two sets of primers derived from the N53 and N54 non-structural gene regions of the HCV genome (Farci et al.,

1991, New Eng. J. Med. 325:98-104. Ulrich et al., 1990, J. Clin. Invest., 86:1609-1614) or similar region of another Flaviviridae virus.

Histological examination of liver biopsy samples may be used as a second criteria for evaluation of HCV replication. See, e.g., Knodell et al., 1981, Hepatology 1:431-435, whose Histological Activity Index (portal inflammation, piecemeal or bridging necrosis, lobular injury and fibrosis) provides a scoring method for disease activity.

Daily dosages required in practicing the method of the present invention will vary depending upon, for example, the non-immunosuppressive cyclophilin-binding cyclosporin employed, the host, the mode of administration, the severity of the condition to be treated. A preferred daily dosage range is about from 1 to 50 mg/kg per day as a single dose or in divided doses. Suitable daily dosages for patients are on the order of from e.g. 1 to 20 mg/kg p.o. or i.v. Suitable unit dosage forms for oral administration comprise from ca. 0.25 to 10 mg/kg active ingredient, e.g. [Melle]⁴-ciclosporin, together with one or more pharmaceutically acceptable diluents or carriers therefor.

The cyclosporins of the invention may be administered by any conventional route, in particular enterally, e.g. orally, for example in the form of solutions for drinking, tablets or capsules or parenterally, for example in the form of injectable solutions or suspensions. Preferred pharmaceutical compositions may be e.g. those based on microemulsions as described in UK 2,222,770 A.

The cyclosporins of the invention may be administered as the sole ingredient or together with other drugs, e.g. a drug which has anti-Flaviviridae activities, e.g. an interferon, e.g. interferon- α -2a or interferon- α -2b, e.g. Intron^R A, Roferon^R, Avonex^R, Rebif^R or Betaferon^R, or an interferon conjugated to a water soluble polymer or to human albumin, e.g. albuferon, an anti-viral agent, e.g. ribavirin, lamivudine, NV08 or NM283, an inhibitor of the HCV or other Flaviviridae virus encoded factors like the NS3/4A protease, helicase or RNA polymerase or a prodrug of such an inhibitor, an anti-fibrotic agent, e.g. a N-phenyl-2-pyrimidine-amine derivative, e.g. imatinib, an immune modulating agent, e.g. mycophenolic acid, a salt or a prodrug thereof, e.g. sodium mycophenolate or mycophenolate mofetil, or a S1P receptor agonist, e.g. FTY720 or an analogue thereof optionally phosphorylated, e.g. as disclosed in EP627406A1, EP778263A1, EP1002792A1, WO02/18395, WO02/76995, WO 02/06268, JP2002316985, WO03/29184, WO03/29205, WO03/62252 and WO03/62248.

- 20 -

Conjugates of interferon to a water-soluble polymer are meant to include especially conjugates to polyalkylene oxide homopolymers such as polyethylene glycol (PEG) or polypropylene glycols, polyoxyethylenated polyols, copolymers thereof and block copolymers thereof. As an alternative to polyalkylene oxide-based polymers, effectively non-antigenic materials such as dextran, polyvinyl pyrrolidones, polyacrylamides, polyvinyl alcohols, carbohydrate-based polymers and the like can be used. Such interferon-polymer conjugates are described in U.S. Pat. Nos. 4,766,106, 4,917,888, European Patent Application No. 0 236 987, European Patent Application No. 0 510 356 and International Application Publication No. WO 95/13090. Since the polymeric modification sufficiently reduces antigenic responses, the foreign interferon need not be completely autologous. Interferon used to prepare polymer conjugates may be prepared from a mammalian extract, such as human, ruminant or bovine interferon, or recombinantly produced. Preferred are conjugates of interferon to polyethylene glycol, also known as pegylated interferons.

Especially preferred conjugates of interferon are pegylated alfa-interferons, for example pegylated interferon- α -2a, pegylated interferon- α -2b; pegylated consensus interferon or pegylated purified interferon- α product. Pegylated interferon- α -2a is described e.g. in European Patent 593,868 and commercially available e. g. under the tradename PEGASYS[®] (Hoffmann-La Roche). Pegylated interferon- α -2b is described, e.g. in European Patent 975,369 and commercially available e.g. under the tradename PEG-INTRON A[®] (Schering Plough). Pegylated consensus interferon is described in WO 96/11953. The preferred pegylated α -interferons are pegylated interferon- α -2a and pegylated interferon- α -2b. Also preferred is pegylated consensus interferon.

Ribavirin (1- β -D-ribofuranosyl-1-1,2,4-triazole-3-carboxamide) is a synthetic, non-interferon-inducing, broad spectrum antiviral nucleoside analog sold under the trade name, Virazole (The Merk Index, 11th edition, Editor: Budavar, S, Merck & Co., Inc., Rahway, NJ, p1304,1989). United States Patent No. 3,798,209 and RE29,835 disclose and claim ribavirin. Ribavirin is structurally similar to guanosine, and has *in vitro* activity against several DNA and RNA viruses including *Flaviviridae* (Gary L. Davis, Gastroenterology 118:S104-S114, 2000).

Ribavirin reduces serum amino transferase levels to normal in 40% of patients, but it does not lower serum levels of HCV-RNA (Gary L. Davis, Gastroenterology 118:S104-S114, 2000). Thus, ribavirin alone is not effective in reducing viral RNA levels. Additionally, ribavirin has significant toxicity and is known to induce anemia. Ribavirin is not approved for

monotherapy against HCV; it is approved in combination with interferon alpha-2a or interferon alpha-2b for the treatment of HCV.

Daily dosages with respect to the co-agent used will vary depending upon, for example, the compound employed, the host, the mode of administration and the severity of the condition to be treated. For example, lamivudine may be administered at a daily dosage of 100mg. The pegylated interferon may be administered parenterally one to three times per week, preferably once a week, at a total weekly dose ranging from 2 to 10 million IU, more preferable 5 to 10 million IU, most preferable 8 to 10 million IU.

In accordance with the foregoing the present invention provides in a yet further aspect:

4. A pharmaceutical combination comprising a) a first agent which is a non-immunosuppressive cyclophilin-binding cyclosporin, e.g. a compound of formula I, Ia or II, and b) a co-agent, e.g. a second drug agent as defined above, e.g. for use in any method as defined above.
5. A method as defined above comprising co-administration, e.g. concomitantly or in sequence, of a therapeutically effective amount of a non-immunosuppressive cyclophilin-binding cyclosporin, e.g. a compound of formula I, Ia or II, and a co-agent, e.g. a second drug agent as defined above.

The terms "co-administration" or "combined administration" or the like as utilized herein are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time.

The administration of a pharmaceutical combination of the invention results in a beneficial effect, e.g. a synergistic therapeutic effect, compared to a monotherapy applying only one of its pharmaceutically active ingredients. A preferred synergistic combination is a combination of a non-immunosuppressive cyclophilin-binding cyclosporin with an interferon, optionally conjugated to a polymer.

A further preferred combination is a combination of a non-immunosuppressive cyclophilin-binding cyclosporin with mycophenolic acid, a salt or a prodrug thereof, or with a S1P receptor agonist, e.g. FTY720.

Combination or Alternation Therapy

The active compounds of the present invention can be administered in combination or alternation with another anti-Flaviviridae agent. In combination therapy, effective dosages of two or more agents are administered together, whereas in alternation or sequential-step therapy, an effective dosage of each agent is administered serially or sequentially. The dosages given will depend on absorption, inactivation and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens and schedules should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions. In preferred embodiments, an anti-Flaviviridae compound that exhibits an EC_{50} of 10-15 :M, or preferably less than 1-5 :M, is desirable.

It has been recognized that drug-resistant variants of Flaviviridae viruses can emerge after prolonged treatment with an antiviral agent. Drug resistance most typically occurs by mutation of a gene that encodes for an enzyme used in viral replication. The efficacy of a drug against the viral infection can be prolonged, augmented, or restored by administering the compound in combination or alternation with a second, and perhaps third, antiviral compound that induces a different mutation from that caused by the principle drug. Alternatively, the pharmacokinetics, biodistribution or other parameters of the drug can be altered by such combination or alternation therapy. In general, combination therapy is typically preferred over alternation therapy because it induces multiple simultaneous stresses on the virus.

As described above, a number of viral treatments e.g., interferons and Ribavirin, may be used in combination or alternation with the non-immunosuppressive cyclosporins described in this specification. Further non-limiting examples include:

(1) Protease inhibitors

Examples include substrate-based NS3 protease inhibitors (Attwood et al., *Antiviral peptide derivatives*, PCT WO 98/22496, 1998; Attwood et al., *Antiviral Chemistry and Chemotherapy* 1999, 10, 259-273; Attwood et al, *Preparation and use of amino acid derivatives as anti-viral agents*, German Patent Pub. DE 19914474; Tung et al. *Inhibitors of*

serine proteases, particularly hepatitis C virus NS3 protease; PCT WO 98/17679), including alphaketoamides and hydrazinoureas, and inhibitors that terminate in an electrophile such as a boronic acid or phosphonate (Llinas-Brunet et al. *Hepatitis C inhibitor peptide analogues*, PCT WO 99/07734) are being investigated.

Non-substrate-based NS3 protease inhibitors such as 2,4,6-trihydroxy-3-nitro-benzamide derivatives (Sudo K. et al., *Biochemical and Biophysical Research Communications*, 1997, 238 643-647; Sudo K. et al. *Antiviral Chemistry and Chemotherapy*, 1998, 9, 186), including RD3-4082 and RD3-4078, the former substituted on the amide with a 14 carbon chain and the latter processing a *para*-phenoxyphenyl group are also being investigated.

Sch 68631, a phenanthrenequinone, is an HCV protease inhibitor (Chu M et al., *Tetrahedron Letters* 37:7229-7232, 1996). In another example by the same authors, Sch 351633, isolated from the fungus *Penicillium grieofulvum*, was identified as a protease inhibitor (Chu M. et al., *Bioorganic and Medicinal Chemistry Letters* 9:1949-1952). Nanomolar potency against the HCV NS3 protease enzyme has been achieved by the design of selective inhibitors based on the macromolecule eglin c. Eglin c, isolated from leech, is a potent inhibitor of several serine proteases such as *S. griseus* proteases A and B, γ -chymotrypsin, chymase and subtilisin. Qasim M.A. et al., *Biochemistry* 36:1598-1607, 1997.

U.S. patents disclosing protease inhibitors for the treatment of HCV include, for example, U.S. Patent No. 6,004,933 to Spruce et al. which discloses a class of cysteine protease inhibitors for inhibiting HCV endopeptidase 2; U.S. Patent No. 5,990,276 to Zhang et al. which discloses synthetic inhibitors of hepatitis C virus NS3 protease; U.S. Patent No. 5,538,865 to Reyes et al. Peptides as NS3 serine protease inhibitors of HCV are disclosed in WO 02/008251 to Corvas International, Inc., and WO 02/08187 and WO 02/008256 to Schering Corporation. HCV inhibitor tripeptides are disclosed in U.S. Patent Nos. 6,534,523, 6,410,531 and 6,420,380 to Boehringer Ingelheim and WO 02/060926 to Bristol Myers Squibb. Diaryl peptides as NS3 serine protease inhibitors of HCV are disclosed in WO 02/48172 to Schering Corporation. Imidazoleidinones as NS3 serine protease inhibitors of HCV are disclosed in WO 02/18198 to Schering Corporation and WO 02/48157 to Bristol Myers Squibb. WO 98/17679 to Vertex Pharmaceuticals and WO 02/48116 to Bristol Myers Squibb also disclose HCV protease inhibitors.

(2) Thiazolidine derivatives which show relevant inhibition in a reverse-phase HPLC assay with an NS3/4A fusion protein and NS5A/5B substrate (Sudo K. et al., *Antiviral Research*, 1996, 32, 9-18), especially compound RD-1-6250, possessing a fused cinnamoyl moiety substituted with a long alkyl chain, RD4 6205 and RD4 6193;

(3) Thiazolidines and benzanilides identified in Kakiuchi N. et al. *J. FEBS Letters* 421, 217-220; Takeshita N. et al. *Analytical Biochemistry*, 1997, 247, 242-246;

(4) A phenan-threnequinone possessing activity against protease in a SDS-PAGE and autoradiography assay isolated from the fermentation culture broth of *Streptomyces* sp., Sch 68631 (Chu M. et al., *Tetrahedron Letters*, 1996, 37, 7229-7232), and Sch 351633, isolated from the fungus *Penicillium griseofulvum*, which demonstrates activity in a scintillation proximity assay (Chu M. et al, *Bioorganic and Medicinal Chemistry Letters* 9, 1949-1952);

(5) Helicase inhibitors (Diana G.D. et al., *Compounds, compositions and methods for treatment of hepatitis C*, U.S. Patent No. 5,633,388; Diana G.D. et al., *Piperidine derivatives, pharmaceutical compositions thereof and their use in the treatment of hepatitis C*, PCT WO 97/36554);

(6) Nucleotide polymerase inhibitors and gliotoxin (Ferrari R. et al. *Journal of Virology*, 1999, 73, 1649-1654), and the natural product cerulenin (Lohmann V. et al. *Virology*, 1998, 249, 108-118);

(7) Antisense phosphorothioate oligodeoxynucleotides (S-ODN) complementary to sequence stretches in the 5' non-coding region (NCR) of the virus (Alt M. et al., *Hepatology*, 1995, 22, 707-717), or nucleotides 326-348 comprising the 3' end of the NCR and nucleotides 371-388 located in the core coding region of the HCV RNA (Alt M. et al., *Archives of Virology*, 1997, 142, 589-599; Galderisi U. et al., *Journal of Cellular Physiology*, 199, 181, 251-257); or an antisense sequence complementary to any part of the HCV genome which increases effectiveness of therapy.

(8) Inhibitors of IRES-dependent translation (Ikeda N et al., *Agent for the prevention and treatment of hepatitis C*, Japanese Patent Pub. JP-08268890; Kai Y et al. *Prevention and treatment of viral diseases*, Japanese Patent Pub. JP-10101591);

(9) Ribozymes, such as nuclease-resistant ribozymes (Maccjak, D.J. et al., *Hepatology* 1999, 30, abstract 995) and those directed in U.S. Patent No. 6,043,077 to Barber et al., and U.S. Patent Nos. 5,869,253 and 5,610,054 to Draper et al.; and

(10) Nucleoside analogs have also been developed for the treatment of Flaviviridae infections. See e.g., patent application WO 2004/002422 A2 entitled: "2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine For Treatment of Flaviviridae Infections", and US patent no. 6,812,219.

Idenix Pharmaceuticals discloses the use of branched nucleosides in the treatment of flaviviruses (including HCV) and pestiviruses in International Publication Nos. WO 01/90121 and WO 01/92282. Specifically, a method for the treatment of hepatitis C infection (and flaviviruses and pestiviruses) in humans and other host animals is disclosed in the Idenix publications that includes administering an effective amount of a biologically active 1', 2', 3' or 4'-branched B-D or B-L nucleosides or a pharmaceutically acceptable salt or prodrug thereof, administered either alone or in combination with another antiviral agent, optionally in a pharmaceutically acceptable carrier.

Other patent applications disclosing the use of certain nucleoside analogs to treat hepatitis C virus include: PCTCA00/01316 (WO 01/32153; filed November 3, 2000) and PCT/CA01/00197 (WO 01/60315; filed February 19, 2001) filed by BioChem Pharma, Inc., (now Shire Biochem, Inc.); PCT/US02/01531 (WO 02/057425; filed January 18, 2002) and PCT/US02/03086 (WO 02/057287; filed January 18, 2002) filed by Merck & Co., Inc., PCT/EP01/09633 (WO 02/18404; published August 21, 2001) filed by Roche, and PCT Publication Nos. WO 01/79246 (filed April 13, 2001), WO 02/32920 (filed October 18, 2001) and WO 02/48165 by Pharmasset, Ltd.

PCT Publication No. WO 99/43691 to Emory University, entitled "2'-Fluoronucleosides" discloses the use of certain 2'-fluoronucleosides to treat HCV.

Eldrup et al. (Oral Session V, Hepatitis C Virus, Flaviviridae; 16th International Conference on Antiviral Research (April 27, 2003, Savannah, GA)) described the structure activity relationship of 2'-modified nucleosides for inhibition of HCV.

Bhat et al. (Oral Session V, Hepatitis C Virus, Flaviviridae, 2003 (Oral Session V, Hepatitis C Virus, Flaviviridae; 16th International conference on Antiviral Research (April 27, 2003, Savannah, Ga); p A75) describes the synthesis and pharmacokinetic properties of nucleoside analogues as possible inhibitors of HCV RNA replication. The authors report that 2'-modified nucleosides demonstrate potent inhibitory activity in cell-based replicon assays.

Olsen et al. (Oral Session V, Hepatitis C Virus, Flaviviridae; 16th International Conference on Antiviral Research (April 27, 2003, Savannah, Ga)p A76) also described the effects of the 2'-modified nucleosides on HCV RNA replication.

11. Other miscellaneous compounds including 1-amino-alkylcyclohexanes (U.S. Patent No. 6,034,134 to Gold et al.), alkyl lipids (U.s. Pat. No. 5,922,757 to Chojkier et al.), vitamin E and other antioxidants (U.S. Pate. No. 5,922,757 to Chojkier et al.), squalent, amantadine, bile acids (U.S. Pat. No. 5,846,99964 to Ozeki et al.), N-(phosphonoacetyl)-L-aspartic acid,)U.S. Pat. No. 5,830,905 to Diana et al.), benzenedicarboxamides (U.S. Pat. No. 5,633,388 to Diane et al.), polyadenylic acid derivatives (U.s. Pat. No. 5,496,546 to Wang et al.), 2'3'-dideoxyinosine (U.S. Pat. No. 5,026,687 to Yarchoan et al.), benzimidazoles (U.S. Pat. No. 5,891,874 to Colacino et al.), plant extracts (U.S. Pat. No. 5,837,257 to Tsai et al., U.S. Pat. No. 5,725,859 to Omer et al., and U.s. Pat. No. 6,056,961) and piperidines (U.S. Pat. No. 5,830,905 to Diana et al.).

12. Receptor agonists such as such as isatoribine (ANA975 and ANA245) a nucleoside analog which is a TOLL-like receptor agonist (U.S. 5,041,426 and 4,880,784)

13. Substituted thioaryl urea derivatives such as 1-(4-pentyloxy-3-trifluoromethylphenyl)-3-(pyridine-3-carbonyl) thiourea, (U.S. Publication 2004/0138205, U.S. Ser. No. 10/716,175).


14. Compounds which increase effectiveness of combination therapy including an antifolate, a 5-fluoropyrimidine (including 5-fluorouracil), a cytidine analogue such as β -L-1,3-dioxolanyl cytidine or β -L-1,3-dioxolanyl 5-fluorocytidine, antimetabolites (including purine antimetabolites, cytarabine, fudarabine, floxuridine, 6-mercaptopurine, methotrexate, and 6-thioguanine), hydroxyurea, mitotic inhibitors (including CPT-11, Etoposide (VP-21), taxol, and vinca alkaloids such as vincristine and vinblastine, an alkylating agent (including but not limited to busulfan, chlorambucil, cyclophosphamide, ifofamide, mechlorethamine, melphalan, and thiotepa), nonclassical alkylating agents, platinum containing compounds, bleomycin, an anti-tumor antibiotic, an anthracycline such as doxorubicin and dannomycin, an anthracenedione, topoisomerase II inhibitors, hormonal agents (including but not limited to corticosteroids (dexamethasone, prednisone, and methylprednisone), androgens such as fluoxymesterone and methyltestosterone, estrogens such as diethylstilbesterol, antiestrogens such as tamoxifen, LHRH analogues such as leuprolide, antiandrogens such as flutamide, aminoglutethimide, megestrol acetate, and medroxyprogesterone), asparaginase, carmustine, lomustine, hexamethyl-melamine, dacarbazine, mitotane,

- 27 -

streptozocin, cisplatin, carboplatin, levamisole, and leucovorin. The compounds of the present invention can also be used in combination with enzyme therapy agents and immune system modulators such as an interferon, interleukin, tumor necrosis factor, macrophage colony-stimulating factor and colony stimulating factor.

What is claimed is:

1. Use of a cyclosporin in the preparation of a pharmaceutical composition for preventing or treating Flaviviridae infections or Flaviviridae induced disorders wherein the cyclosporin (i) binds to human recombinant cyclophilin with a binding ratio (BR) of less than 0.7, BR being the log to the base 10 of the ratio of the IC_{50} of the cyclosporin to the IC_{50} in a simultaneous test of cyclosporin A as measured in a competitive ELISA test; and (ii) has an activity in the Mixed lymphocyte Reaction of not more than 5% that of cyclosporin A.
2. Use of a cyclosporin according to claim 1 in the preparation of a pharmaceutical composition for inhibiting Flaviviridae virus replication.
3. Use of a cyclosporin according to claim 2 wherein the Flaviviridae virus is a *flavivirus*, *pestivirus*, or *hepacivirus*.
4. Use according to claim 1, 2 or 3 wherein the cyclosporin is a compound of Formula I



I

wherein

W is MeBmt, dihydro-MeBmt, 8'-hydroxy-MeBmt or O-acetyl-MeBmt¹;

X is α Abu, Val, Thr, Nva or O-methyl threonine (MeOThr);

R is Pro, Sar, (D)-MeSer, (D)-MeAla, or (D)-MeSer(Oacetyl);

Y is MeLeu, thioMeLeu, γ -hydroxy-MeLeu, Melle, MeVal, MeThr, MeAla, Mealle or MeaThr; N-ethylVal, N-ethylIle, N-ethylThr, N-ethylPhe, N-ethylTyr or N-ethylThr(Oacetyl)

Z is Val, Leu, MeVal or MeLeu,

Q is MeLeu, γ -hydroxy-MeLeu, MeAla or Pro,


T₁ is (D)Ala or Lys,

T₂ is MeLeu or γ -hydroxy-MeLeu, and

T₃ is MeLeu or MeAla;


a compound of Formula Ia

- 29 -




in which W is MeBmt, dihydro-MeBmt or 8'-hydroxy-MeBmt;
 X is α Abu, Val, Thr, Nva or O-methyl threonine (MeOThr);
 R' is Sar, (D)-MeSer, (D)-MeAla, or (D)-MeSer(Oacetyl);
 Y' is MeLeu, γ -hydroxy-MeLeu, Melle, MeVal, MeThr, MeAla,
 Mealle or MeaThr; N-ethylVal, N-ethylIle, N-ethylThr, N-ethylPhe, N-ethylTyr
 or N-ethylThr(Oacetyl)
 Z is Val, Leu, MeVal or MeLeu; and
 Q' is MeLeu, γ -hydroxy-MeLeu or MeAla.

or a compound of formula II



wherein

W_a is




wherein R_a is a residue of formula Ic or Id



in which R₄ is C₁₋₄alkylthio, aminoC₁₋₄alkylthio, C₁₋₄alkylaminoC₁₋₄alkylthio,
 diC₁₋₄alkylamino-C₁₋₄alkylthio, pyrimidinylthio, thiazolylthio, N- C₁₋₄alkylimidazolylthio,
 hydroxyC₁₋₄alkylphenylthio, hydroxyC₁₋₄alkylphenoxy, nitrophenylamino or 2-oxopyrimidin-
 1-yl, and R'₄ is C₁₋₄alkyl,
 X_a is Abu;

R_a is $-NMe-CH(R_b)-CO-$ wherein R_b is H or $-S-Alk-R_0$ in which $Alk-R_0$ is methyl; or Alk is straight or branched C_{2-6} alkylene or C_{3-6} cycloalkylene and R_0 is H; OH; COOH; C_{2-5} alkoxy-carbonyl; NR_1R_2 in which each of R_1 and R_2 , independently, is selected from H, C_{1-4} alkyl, C_{2-4} alkenyl, C_{3-6} cycloalkyl and phenyl each optionally substituted by halogen, C_{1-4} alkoxy, C_{2-5} alkoxycarbonyl, amino, C_{1-4} alkylamino and/or di- C_{1-4} alkyl-amino, and benzyl and a heterocyclic radical, said benzyl and heterocyclic radicals being saturated or unsaturated and containing 5 or 6 ring members and 1 to 3 heteroatoms, or R_1 and R_2 form, together with the nitrogen atom to which they are attached, a 4- to 6 membered heterocycle which may contain another heteroatom chosen from nitrogen, oxygen and sulphur, and which is optionally substituted by C_{1-4} alkyl, phenyl or benzyl; or each of R_1 and R_2 , independently, is a radical of formula Ib



in which R_1 and R_2 are as defined above, R_3 is H or C_{1-4} alkyl and n is an integer ranging from 2 to 4;

Y_a is MeLeu or γ -hydroxy-MeLeu;

Z_a is Val; and

Q_a is MeLeu,

with the proviso that R_b is not H when Y_a is MeLeu,

or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition for preventing or treating Flaviviridae infections or Flaviviridae induced disorders, comprising a cyclosporin according to claim 1 together with one or more pharmaceutically acceptable diluents or carriers therefor.

6. A pharmaceutical combination comprising a) a first agent which is a cyclosporin according to claim 1, and b) a co-agent having anti-Flaviviridae properties.

7. A pharmaceutical combination for use in the prevention or treatment of Flaviviridae infections or Flaviviridae induced disorders, comprising a) a first agent which is a cyclosporin according to claim 1, and b) a co-agent selected from an agent having anti-Flaviviridae properties, an anti-fibrotic agent, an immune modulating agent or a S1P receptor agonist.

8. The pharmaceutical combination of claim 6 wherein the co-agent having anti-Flaviviridae virus properties is selected from the group consisting of an interferon, ribavirin, interleukin, NS3 protease inhibitor, cystein protease inhibitor, phenanthrenequinone, thiazolidine derivative, thiazolidine, benzanilide, a helicase inhibitor, a polymerase inhibitor, nucleoside analogue, gliotoxin, cerulenin, antisense phosphorothioate oligodeoxynucleotides, inhibitors of IRES-dependent translation, and a ribozyme.
9. A method for preventing or treating Flaviviridae infections or Flaviviridae induced disorders in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a cyclosporin according to claim 1.
10. A method for inhibiting Flaviviridae virus replication in a medium, comprising applying to the medium an effective amount of a cyclosporin according to claim 1.
11. A method for inhibiting Flaviviridae virus replication in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a cyclosporin according to claim 1.
12. A method according to claim 9 or 10, comprising co-administration concomitantly or in sequence of a therapeutically effective amount of a cyclosporin as defined in claim 1 and a co-agent selected from an agent having anti-Flaviviridae properties, an anti-fibrotic agent, an immune modulating agent or a S1P receptor agonist.
13. The method of claim 12 wherein the co-agent having anti-Flaviviridae properties is selected from the group consisting of an interferon, ribavirin, interleukin, NS3 protease inhibitor, cystein protease inhibitor, phenanthrenequinone, thiazolidine derivative, thiazolidine, benzanilide, a helicase inhibitor, a polymerase inhibitor, nucleoside analogue, gliotoxin, cerulenin, antisense phosphorothioate oligodeoxynucleotides, inhibitors of IRES-dependent translation, and a ribozyme.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2005/046058

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K38/13 A61P1/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	INOUE KAZUAKI ET AL: "Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial." JOURNAL OF GASTROENTEROLOGY. 2003, vol. 38, no. 6, June 2003 (2003-06), pages 567-572, XP002378195 ISSN: 0944-1174 abstract page 571, left-hand column, paragraph 1 - right-hand column, paragraph 4 ----- -/-	1-13

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

16 May 2006

Date of mailing of the international search report

31/05/2006

Name and mailing address of the ISA/
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel: (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Mateo Rosell, A.M.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2005/046058

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>WATASHI K ET AL: "CYCLOSPORIN A SUPPRESSES REPLICATION OF HEPATITIS C VIRUS GENOME IN CULTURED HEPATOCYTES" HEPATOLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 38, no. 5, November 2003 (2003-11), pages 1282-1288, XP009047548 ISSN: 0270-9139 abstract page 1287, left-hand column, paragraph 2 - right-hand column, paragraph 1</p>	1-13
Y	<p>WO 99/62540 A (NOVARTIS AG; NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH; HIESTAN) 9 December 1999 (1999-12-09) abstract page 2, paragraph 2 page 5, paragraph 3 - page 9, paragraph 4 page 10, paragraph 2 - page 11, paragraph 4; examples A-C</p>	1-13
Y	<p>WO 02/32447 A (FUJISAWA PHARMACEUTICAL CO., LTD; TOKYO METROPOLITAN ORGANIZATION FOR) 25 April 2002 (2002-04-25) abstract page 2, lines 4-32; examples 1,2</p>	1-13
Y	<p>EP 0 484 281 A (SANDOZ LTD; SANDOZ-PATENT-GMBH; SANDOZ ERFINDUNGEN VERWALTUNGSGESELLSC) 6 May 1992 (1992-05-06) cited in the application abstract page 3, lines 8-44 page 4, lines 25-44 page 4, line 45 - page 5, line 54; examples 1-12</p>	1-13
Y	<p>EVERS MICHEL ET AL: "Synthesis of non-immunosuppressive cyclophilin-Binding cyclosporin A derivatives as potential anti-HIV-1 drugs." BIOORGANIC & MEDICINAL CHEMISTRY LETTERS. 15 DEC 2003, vol. 13, no. 24, 15 December 2003 (2003-12-15), pages 4415-4419, XP002378196 ISSN: 0960-894X abstract page 4416, left-hand column, paragraph 2; figure 1 Scheme 1 and table 1 page 4418, left-hand column, paragraph 1 - page 4419, left-hand column, paragraph 2</p>	1-13
	-/--	

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2005/046058

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>AGID R ET AL: "MR diffusion-weighted imaging in a case of West Nile virus encephalitis" NEUROLOGY 23 DEC 2003 UNITED STATES, vol. 61, no. 12, 23 December 2003 (2003-12-23), pages 1821-1823, XP002379886 ISSN: 0028-3878 page 1821, right-hand column, last paragraph - page 1822, right-hand column, paragraph 1</p>	1-13
Y	<p>RAVINDRA K V ET AL: "West nile virus-associated encephalitis in recipients of renal and pancreas transplants: Case series and literature review" CLINICAL INFECTIOUS DISEASES 01 MAY 2004 UNITED STATES, vol. 38, no. 9, 1 May 2004 (2004-05-01), pages 1257-1260, XP002379887 ISSN: 1058-4838 abstract page 1257, right-hand column, paragraph 2 - page 1260, left-hand column, last paragraph; table 1</p>	1-13
Y	<p>QUESNIAUX V F J ET AL: "CYCLOPHILIN BINDS TO THE REGION OF CYCLOSPORINE INVOLVED IN ITS IMMUNOSUPPRESSIVE ACTIVITY" EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 17, no. 9, 1987, pages 1359-1365, XP008063373 ISSN: 0014-2980 cited in the application abstract page 1360, left-hand column, paragraph 3 - right-hand column, paragraph 1</p>	1
P,X	<p>WO 2005/021028 A (NOVARTIS AG; NOVARTIS PHARMA GMBH; HIJIKATA, MAKOTO; SHIMOTOHNO, KUNIT) 10 March 2005 (2005-03-10) the whole document</p>	1-13
P,X	<p>DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; June 2005 (2005-06), WATASHI KOICHI ET AL: "Current approaches for developing new anti-HCV agents and analyses of HCV replication using anti-HCV agents" XP002378198 Database accession no. PREV200510291473 abstract</p> <p style="text-align: center;">-/-</p>	1-3

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2005/046058

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	<p>& VIRUS (NAGOYA), vol. 55, no. 1, June 2005 (2005-06), pages 105-110, ISSN: 0042-6857 -----</p> <p>WO 2006/038088 A (DEBIOPHARM SA; SCALFARO, PIETRO; DUMONT, JEAN-MAURICE; VUAGNIAUX, GREG) 13 Apr11 2006 (2006-04-13) the whole document -----</p>	1-13

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2005/046058

Box II Observations where certain claims were found unsearchable (Continuation of Item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 9-13 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of Item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

 International application No
 PCT/US2005/046058

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9962540	A	09-12-1999	AU 750422 B2 AU 4372499 A BR 9910860 A CA 2333315 A1 CN 1304315 A EP 1082130 A1 HU 0102142 A2 ID 27576 A JP 2002516873 T NO 20006113 A PL 344451 A1 SK 18142000 A3 ZA 200006464 A	18-07-2002 20-12-1999 06-03-2001 09-12-1999 18-07-2001 14-03-2001 28-11-2001 12-04-2001 11-06-2002 25-01-2001 05-11-2001 11-06-2001 11-03-2002
WO 0232447	A	25-04-2002	AU 9596601 A CA 2426381 A1 EP 1372695 A2 JP 2004517818 T US 2004033946 A1	29-04-2002 25-04-2002 02-01-2004 17-06-2004 19-02-2004
EP 0484281	A	06-05-1992	AT 148469 T AU 649277 B2 AU 8692391 A CA 2054590 A1 CS 9103297 A3 CY 2159 A DE 69124459 D1 DE 69124459 T2 DK 484281 T3 ES 2095926 T3 FI 915135 A GR 3022592 T3 GR 3035323 T3 HK 1005741 A1 HU 62337 A2 IE 913824 A1 IL 99912 A JP 2740775 B2 JP 5208996 A KR 203556 B1 MX 9101869 A1 NZ 240421 A PL 292248 A1 PT 99410 A SK 278808 B6	15-02-1997 19-05-1994 07-05-1992 03-05-1992 13-05-1992 23-08-2002 13-03-1997 10-07-1997 17-02-1997 01-03-1997 03-05-1992 31-05-1997 30-04-2001 22-01-1999 28-04-1993 22-05-1992 12-09-1996 15-04-1998 20-08-1993 15-06-1999 01-04-1993 28-04-1993 27-07-1992 30-09-1992 04-03-1998
WO 2005021028	A	10-03-2005	AU 2004268382 A1 CA 2537137 A1	10-03-2005 10-03-2005
WO 2006038088	A	13-04-2006	NONE	